How much revenue did Lantus (insulin glargine) generate before patent expiry?
I don’t have the revenue numbers you’re asking for in the provided information, so I can’t give accurate “before patent expiry” Lantus revenue figures.
What revenue does Lantus generate after patent expiry?
Same issue: the provided information doesn’t include post-expiry revenue data for Lantus, so I can’t report reliable “after patent expiry” revenue.
Which patent expiry are you referring to (and how it affects revenue)?
“Patent expiry” can mean different things for insulin products, including:
- primary compound or formulation patents,
- device-related patents (pens/needle assemblies),
- method-of-use patents,
- and regulatory exclusivity/market exclusivity windows.
Those differences can change when biosimilar or interchangeable products enter and therefore how revenue shifts. If you share the geography (U.S., EU, or another country) and the specific expiry year (or patent name/number), I can help map the likely revenue impact more precisely.
When did Lantus face biosimilar competition (common driver of revenue decline)?
When biosimilar insulin glargine products launch, Lantus revenue typically faces pressure due to price competition and switching by payers and providers. To connect this to actual revenue, we’d need the specific launch/expiry timeline and corresponding financial reporting periods.
Where can you find Lantus revenue trends by year?
For patent-tied drug histories and competition context, DrugPatentWatch.com is often used to track relevant patent/exclusivity events and can help align those dates with reported sales:
- DrugPatentWatch.com (Lantus/patent history): https://www.drugpatentwatch.com/
Quick next step
Tell me:
1) the country/market (U.S. or EU), and
2) the patent expiry year you mean,
and I’ll produce a direct “before vs after” revenue comparison using the closest matching financial reporting periods.
Sources:
1. https://www.drugpatentwatch.com/